Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah rubs1, that might be a good reason.
Management did nothing serious to give shareholders reason, not to have confidence anymore. I would guess, instead, that some shareholders would expect more within a short period, but which is not achievable by management.
Seems that someone left patience. Why did someone dump his shares?
Oh yeah, thank you for the notice. Nearly 30% down, hhm ...
But on the other side a rather good volume compared to former days.
Vitamin B12 and Gallium would make a nice compound. Not yet patented by Genta, but they should maybe synthesize it.
Yeah, what else should you do? Just waiting.
At least the use of vitamine B12 as a ligand for metal chelation is a similar adaption of their Eligen technology. Vitamine B12 acts as a carrier compound in the same way as their other compund library.
With respect of the mining activities I have added some comments after a in-deep research from a user "nodummy" from this board, who has given some interesting connections, but that was two years ago, I guess. I posted my comments to that already last year, so it might be outdated. But Bayport holds some mining interest in a gold mine, and what's going on with their mining activities, I haven't heard anything newer that you.
So we have to wait, if they confirm, that they are still active in that business.
Yeah, unfortunately now we considerably low compared to post-R/S level. On the long run, I hope we will get over this level again.
Hi Johnny, those buyers seems to expect some uptrend too. I have a positive opinion with it, too.
Undervalued or not, some improvments in company structure like the audit and business delelopment in the oil-gas field, and mining activities could give pps a run.
We had several other days with that volume, so this is probably under daily average.
There are some buyers now, hope pps will hold that level to the end of the day.
The Eligen Technology is a technology which adapts to the problem to be solved. The structure library of Emisphere is adopted to a specific problem, when a customer contacts them. Then they look after the customer needs, and than they put those compounds out of their shelf to produce a customer-centered solution.
Do you think of averaging down here for maybe an easier reach of break even point, when we see an increase in pps?
Hhhm, the decline has not continued today.
As I found out, pps very often never reflects any thing that a company is doing. It should, but often pps does do the opposite or nothing. Therefore here we only can hope, that they speed up their businesss, if they are able to do so.
I wound't think that low pps is associated with "bad events", at least not necessarily.
Emisphere used its own technology, the Eligen technology, to prepare new formulations of Oral Gallium, G4544.
They put out a company report in the beginning of 2014 for 2013. But I would guess, that in 2014 due to more and new cooperations, they will increase their income. But first they has to fix the problems associated with the new wells.
What else should they do?
I'm confident, that they still work on the announced matter(s), but they can't update shareholders every two weeks. That's normal I would guess.
Some more information can be obtained from some 8K filings, reported by Emishere Technology in 2006, e.g.:
http://files.shareholder.com/downloads/EMIS/0x0xS1299933-06-2233/805326/filing.pdf
That's an old link, but I found the same also on other PR sites:
http://www.prnewswire.com/news-releases/genta-announces-initial-clinical-trial-results-for-g4544-a-novel-potent-drug-for-bone-disease-57306112.html
That's already a long time ago, when they started the studies with the gallium containing compound. I remember back, that they had also trails against cystic fibrosis with Gallium-containing substances.
No, I'm no exactely saying, that I am total confident with management, because they not yet made what they announced. But to be honest, they did not gave an exact timeline, when they wanted to fullfill their promise. I have never said that we all will be rich, because this really seldom happens, and to be honest it's more likely a dream, than something which happens in reality.
But I'm still confident, that they can bring those work to a good end, what they have begun, because that was a good idea, to cooperate with other partners in the same business, to strenghten their own business.
I agree with you, but as shareholder I invest in a company while I like their style, their products or because I trust them, even if they do sometimes "stupid" decisions.
It's not the duty of a poster at a message board to convince management what they should do or not. It is the duty of the managment to create shareholder value, and they should do this independently to find their own decision. If they have the right people to ask for advice, there is no reason, that this will not work out finally. They create marketable products, which will find their market place within time.
When producing a cosmetic cream using hemp seed oil, they probably do not use the original, virgin seed oil, but convert it before introduction it to cream manufacture.
Hemp seed oil contains high content of organic acids, which have not a favourable action on skin due to their acidity. The virgin hemp seed oil is therefore treated with ethanol to convert the acids to esters. The excess ethanol, which is used in this conversion step, is removed by destillation in vaccum. During the removal of the excess organic solvent, all other volatile constituents, predominately the cannabinoids, are also destilled away due to their volatile characters. The residue, which contains mostly the fatty acid esters is than used with favourable action in the production of skin creams.
The level of cannabionoids in cosmetics therefore is reduced um serveral levels, and this contributes additional to the product safety of the skin creams.
If there are remaining very, very low levels of cannabinoids in the hemp seed oil preparations, they might have a synergistic effect on the "feeling of the cream" on a human skin. The action can be considered to be synergistic to a smoothing, relaxing feeling. These remaining levels of cannabiniods in skin creams are still much too low to produce a considerable level in a users' urine, not compareable to those levels when smoking a MJ cigarette.
I reside within the reach of the places, where I could trade this stock.
I remember, that it was a promotion campagne. But I didn't take part, since I'm not a resident of the USA. Shipping cost will be high, and it takes probably 3 weeks to arrive.
They are probably not worried about the Feds, because the experts all know, that hemp seed oil is safe with respect of any "abuse" action derived from cannabionoids. Therefore, someone claiming he got intoxicated from using a cream produced from it, can easily be denied to follow his opinion.
The reality is, that hemp seed oil is already used in cosmetic industry as favourable ingredient for cosmetic manufacture. But none of the producer is stating, that the oil base is derived from hemp seed oil.
Why not? He will find the same constituents, which are present in sunflower as well in hemp seed oil as main ingredients.
With respect of the cannabinoids, the one who is searching after them, would be able to find them if he has an extraordinary sensitive equipment and very skilled personel. That makes the analysis very expensive, so this could afford only a very small group of people/special equipped laboratories, etc. A normal consumer could not afford a single analysis to substitute his unproven claim. The results is, that Bayport as producer has changed the burden of proof.
Cannabinoids in that content range (sub-nanogram-scale), in which they are maybe found in an analysis, have no physiological action on a user of the cream at all. If a user than nonetheless claims, he got intoxicated from the cream, than Bayport could claim, that the equipment was contaminated before with cannabinoids or the personel running the analysis where smoking cannabis during performing the analysis.
Yes, that is another problem, which might occur.
But it is not impossible to solve this, too. Just make a marketing campagne, and claim, that the oil used in the manufacture has miracle power. The oil claimed to be used in the manufacture of the cream must be announced to be derived from a plant, that has a better reputation than the hemp seed oil.
Both oils have similar ingredients, but a somewhat differing profile in some constituents or a somewhat differing content of ingredients. Just claim in the marketing campagne that the oil used is sunflower oil, or Aloe Vera oil.
So how to overcome the promblem, and still be able to use the favourable and valueable properties of the hemp seed oil?
At least that's very simple, because it is not needed to list the hemp seed oil itself in the list of the ingredients, but rather the single main ingedients.
So the ingredient list on the cream should read:
alpha-linoleic acid, linolenic acid, tocopherol, etc.
The cannabinoids, of course, need not to be listed, because their content is in the sub-nanogram scale.
I don't worry about Bayport's decision on the exit from the MJ business.
Besides the scientific evidence, that hemp seed oil in cosmetics do not lead to "drug abuse", management of Bayport should also think of other safety aspects.
For example, the following situation could occur:
If a user of Bayport's cosmetics claims, after he/she lost a job, or he/she did not get a job after a positive urine test on cannabionoid testing, he/she lost the job because he/she used the cosmetics, that might bring Bayport in a unwanted position inside a law suite.
Although it's clear from the scientific point, that the "high" cannabionoid levels in the users' urine could not be derived from the use of the cosmetics, it might come from the "abuse"/use of smoking a MJ cigarettes with friends at the same time.
How could Bayport win the law suit? Probably this will only costs enormous funds, not worth the law suit. Therefore, it might be a wise decision of Bayport's management, to exit the MJ business not for reasons connected with the science, but connected with the financial risks associated by misuse of false claims against Bayport. Product safety of skin creams with hemp seed oil from the scientific side is very likely, but not from the side of misuse.
The lastest and best available uptodate publication with nearly all relevant references was published two month ago:
Handbook of Cannabis (ed. Roger Pertwee), Oxford University Press, 2014, 784 p. ISBN 978-0-19-966268-5
http://ukcatalogue.oup.com/product/9780199662685.do
http://www.amazon.com/Handbook-Cannabis-Roger-Pertwee/dp/0199662681
"The moral rights of the author have been asserted"
Latest research by Franjo Grotenhermen and Leson Environmental Consulting (a noteworthy, reliable research consulting group) shed considerable light on the use of hemp seed oil, when used in foods or in cosmetics. [36,37]. From these studies, it can be concluded, that there is no risk concerning conflicts with law using hemp seed oil as ingredient in cosmetics.
[36] Petra Pless; Gero Leson: Assessing the impact of thc uptake from hemp oil cosmetics on workplace drug testing. Leson Environmental Consulting. Hemp Oil Cosmetics and Drug Testing 2001, iii, 27 pp. http://www.votehemp.com/PDF/Transdermal_THC_final.PDF
[37] Franjo Grotenhermen; Petra Pless; Gero Leson; Assessment of exposure to and human health risk from thc and other cannabinoids in hemp foods. Leson Environmental Consulting, 2001, 95 p.
http://ameccda.org/thc/Assesment%20of%20exposure%20to%20and%20human%20health%20risk%20from%20THC%20and%20other%20Cannabinoids%20in%20HEMP%20Foods.pdf
The same opinion is shared by James Geiwitz:
[38] THC in Hemp Foods and Cosmetics: The Appropriate Risk Assessment. by James Geiwitz, Ph.D., http://peakoil.transglobalhemp.com/ResponseFinal.pdf
Bayport’s use of hemp seed oil is not intended as a food additive, but in the use of an additive in a cosmetic formulation. Therefore, cannabinoid levels in humans can only raise, if there is a considerable uptake through the skin. In addition, cannabinoid content of the seed oil can be easily reduced, when the kernels are washed with an organic solvent before oil processing. [34]
As an advice to Bayport’s management, it is possible to use hemp seed oil as an ingredient in a cosmetic formulation, without danger, that consumers come in conflict with current laws. Cannabinoid uptake through the human skin is low, and there has to be applied considerable high creams contents, to raise the detectable level of cannabionoid metabolites in human urine and/or blood.
Therefore, Bayport should use hemp seed oil in the fabrication of its new, revolutionary skin creams. The choice of the manufacture company and/or manufacturing process for the needed hemp seed oil can reduce cannabinoid content in the seed oil, too.
[34] Samir A. Ross; Zlatko Mehmedic, Timothy P. Murphy and Mahmoud A. ElSohly: GC-MS analysis of the total 9-THC content of both drug- and fiber-type cannabis seeds. Anal Toxicol 24 (8): 2000, 715-717. doi: 10.1093/jat/24.8.715
Ingestion of hemp seed oil from the usage as a nutritional oil in humans led to very small, but detectable amounts of cannabinoids in the urin. [35]
[35] T. Lehmann; F. Sager; R. Brenneisen: Excretion of cannabinoids in urine after ingestion of cannabis seed oil. J Anal Toxicol 21 (5): 1997, 373-375. doi: 10.1093/jat/21.5.373
With respect of cannabinoid content of the seed oil, it can be concluded, that hemp seed oil contains very low concentrations of cannabinoids. [33] Theses compounds are mainly concentrated on the surface of the kernel, due to their volatile properties. [34]
[33] T.Z. Bosy and K.A. Cole: Consumption and quantitation of Tetrahydrocannabinol in commercially available hemp seed oil products. J Anal Toxicol (2000) 24 (7): 562-566. doi: 10.1093/jat/24.7.562
[34] Samir A. Ross; Zlatko Mehmedic, Timothy P. Murphy and Mahmoud A. ElSohly: GC-MS analysis of the total 9-THC content of both drug- and fiber-type cannabis seeds. Anal Toxicol 24 (8): 2000, 715-717. doi: 10.1093/jat/24.8.715
Based on previous publications regarding chemical composition of the plants and their chemotaxonomical relationship, various authors published highly interesting articles:
[23] John A. Beutler, Ara H. Marderosian. Chemotaxonomy of Cannabis I. Crossbreeding between Cannabis sativa and C. ruderalis, with analysis of cannabinoid content. Economic Botany 32 (4): 1978, 387-394.
[24] Mölleken, H. and H. Husmann. Cannabinoids in seed extracts of Cannabis sativa cultivars. Journal of the International Hemp Association 4(2): 1997, 73, 76-79. ISSN 1381-091X
[25] Oil content, tocopherol composition and fatty acid patterns of the seeds of 51 Cannabis sativa L. genotypes. Euphytica, 137: 2004, 339–351.
[26] E.P.M. De Meijer: H.J. Van der Kamp; F.A. Van Eeuwijk: Characterisation of Cannabis accessions with regard to cannabinoid content in relation to other plant characters. Euphytica 62: 1992, 187-200.
[27] E.P.M. De Meijer; M. Bagotta; A. Carboni: The inheritance of chemical phenotype in Cannabis sativa L. (I): Genetics 163: 2003, 335-346.
[28] E.P.M. De Meijer; K.M. Hammond: The inheritance of chemical phenotype in Cannabis sativa L. (II): cannabigerol predominant plants. Euphytica, 145: 2005, 189-198.
[29] E.P.M. De Meijer; K.M. Hammond; M. Micheler: The inheritance of chemical phenotype in Cannabis sativa L. (III): variation in cannabichromene proportion. Euphytica, 165: 2009, 293-311.
[30] E. P. M. de Meijer; K. M. Hammond; A. Sutton: The inheritance of chemical phenotype in Cannabis sativa L. (IV): cannabinoid-free plants. Euphytica, 168: 2009, 95-112.
[31] E. P. M. de Meijer; L.C.P. Keizer: Patterns of diversity in Cannabis. Genetic Resources and Crop Evaluation 43, 1996, 41-52.
[32] E. P. M. de Meijer: The chemical phenotypes (chemotypes) of Cannabis. In: Handbook of Cannabis (ed. Roger Pertwee), p. 89-110; Oxford University Press, 2014, 784 p. ISBN 978-0-19-966268-5